Phase IIb Open-label Trial of SUBA-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

Trial Profile

Phase IIb Open-label Trial of SUBA-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Itraconazole (Primary)
  • Indications Basal cell nevus syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms SCORING
  • Sponsors HedgePath Pharmaceuticals
  • Most Recent Events

    • 01 Feb 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.
    • 01 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
    • 11 Jan 2018 Based on the data from this trial Mayne Pharma filed for Orphan Designation in Europe with the EMA (European Medicines Agency) in 2017 and orphan designation was granted for the SUBA-Itraconazole treatment of BCCNS, according to a HedgePath Pharmaceuticals media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top